Literature DB >> 28993096

Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells.

Fatjon Leti1, Christophe Legendre2, Christopher D Still3, Xin Chu3, Anthony Petrick3, Glenn S Gerhard4, Johanna K DiStefano5.   

Abstract

In the present study, we sought to identify long noncoding RNA (lncRNA) expression profiles in nonalcoholic steatohepatitis (NASH) patients with histologic evidence of lobular inflammation and advanced fibrosis. We profiled lncRNA expression using RNA-sequencing of wedge liver biopsies from 24 nonalcoholic fatty liver disease (NAFLD) patients with normal liver histology, 53 NAFLD patients with lobular inflammation, and 65 NAFLD patients with advanced fibrosis. Transcript profiling identified 4432 and 4057 differentially expressed lncRNAs in comparisons of normal tissue with lobular inflammation and fibrosis samples, respectively. Functional enrichment analysis revealed lncRNA participation in transforming growth factor beta 1 and tumor necrosis factor signaling, insulin resistance, and extracellular matrix maintenance. Several lncRNAs were highly expressed in fibrosis relative to normal tissue, including nuclear paraspeckle assembly transcript 1, hepatocellular carcinoma upregulated lncRNA, and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1). Two potential target mRNAs, syndecan 4 (SDC4), and C-X-C motif chemokine ligand 5 (CXCL5) were identified for hepatocellular carcinoma upregulated lncRNA and MALAT1, respectively, but only CXCL5 showed differential expression among the different histologic classes. Knockdown of MALAT1 expression reduced CXCL5 transcript and protein levels by 50% and 30%, respectively, in HepG2 cells. The expression of MALAT1 and CXCL5 was upregulated in activated hepatic stellate (LX-2) cells compared to cells in the quiescent state, and MALAT1 expression was regulated by hyperglycemia and insulin in HepG2 cells, but only by insulin in LX-2 cells. Dysregulated lncRNA expression is associated with inflammation and fibrosis in NASH. Functionally relevant differences in MALAT1 expression may contribute to the development of fibrosis in NASH through mechanisms involving inflammatory chemokines.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28993096      PMCID: PMC5705449          DOI: 10.1016/j.trsl.2017.09.001

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  71 in total

Review 1.  Unique features of long non-coding RNA biogenesis and function.

Authors:  Jeffrey J Quinn; Howard Y Chang
Journal:  Nat Rev Genet       Date:  2016-01       Impact factor: 53.242

2.  Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C.

Authors:  Tarik Asselah; Ivan Bièche; Ingrid Laurendeau; Valérie Paradis; Dominique Vidaud; Claude Degott; Michelle Martinot; Pierre Bedossa; Dominique Valla; Michel Vidaud; Patrick Marcellin
Journal:  Gastroenterology       Date:  2005-12       Impact factor: 22.682

Review 3.  Molecular mechanisms of long noncoding RNAs.

Authors:  Kevin C Wang; Howard Y Chang
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

Review 4.  Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective.

Authors:  Leslie R Bisset; Peter Schmid-Grendelmeier
Journal:  Curr Opin Pulm Med       Date:  2005-01       Impact factor: 3.155

5.  Genome-wide analysis of long noncoding RNA expression profiles in patients with non-alcoholic fatty liver disease.

Authors:  Chuanzheng Sun; Xunyang Liu; Zhongjie Yi; Xuefei Xiao; Mingshi Yang; Gui Hu; Huaizheng Liu; Liangkan Liao; Feizhou Huang
Journal:  IUBMB Life       Date:  2015-10-16       Impact factor: 3.885

6.  Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA.

Authors:  Katrin Panzitt; Marisa M O Tschernatsch; Christian Guelly; Tarek Moustafa; Martin Stradner; Heimo M Strohmaier; Charles R Buck; Helmut Denk; Renée Schroeder; Michael Trauner; Kurt Zatloukal
Journal:  Gastroenterology       Date:  2006-08-14       Impact factor: 22.682

Review 7.  Progress and Prospects of Long Noncoding RNAs (lncRNAs) in Hepatocellular Carcinoma.

Authors:  Chen Li; Jing Chen; Kai Zhang; Bing Feng; Rui Wang; Longbang Chen
Journal:  Cell Physiol Biochem       Date:  2015-05-11

8.  The potential of CXCL5 as a target for liver cancer - what do we know so far?

Authors:  Jinglin Xia; Xiaojing Xu; Peixin Huang; Mingyan He; Xiangdong Wang
Journal:  Expert Opin Ther Targets       Date:  2014-12-11       Impact factor: 6.902

9.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

10.  Plasma level of metastasis-associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma.

Authors:  Hirotaka Konishi; Daisuke Ichikawa; Yusuke Yamamoto; Tomohiro Arita; Katsutoshi Shoda; Hidekazu Hiramoto; Junichi Hamada; Hiroshi Itoh; Yuji Fujita; Shuhei Komatsu; Atsushi Shiozaki; Hisashi Ikoma; Toshiya Ochiai; Eigo Otsuji
Journal:  Cancer Sci       Date:  2016-02-09       Impact factor: 6.716

View more
  34 in total

Review 1.  Long Noncoding RNAs and Human Liver Disease.

Authors:  Johanna K DiStefano; Glenn S Gerhard
Journal:  Annu Rev Pathol       Date:  2021-08-20       Impact factor: 32.350

Review 2.  Roles of long noncoding RNAs on tumor immune escape by regulating immune cells differentiation and function.

Authors:  Lisha Chang; Juan Li; Jie Ding; Yifan Lian; Chaonan Huangfu; Keming Wang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 3.  Long noncoding RNA H19 - a new player in the pathogenesis of liver diseases.

Authors:  Zhihong Yang; Ting Zhang; Sen Han; Praveen Kusumanchi; Nazmul Huda; Yanchao Jiang; Suthat Liangpunsakul
Journal:  Transl Res       Date:  2020-11-20       Impact factor: 10.171

Review 4.  Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn's Disease: The Path From Bench to Bedside.

Authors:  Long-Yuan Zhou; Si-Nan Lin; Florian Rieder; Min-Hu Chen; Sheng-Hong Zhang; Ren Mao
Journal:  Inflamm Bowel Dis       Date:  2021-06-15       Impact factor: 7.290

5.  Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage.

Authors:  Silvia Sookoian; Diego Flichman; Martin E Garaycoechea; Julio San Martino; Gustavo O Castaño; Carlos J Pirola
Journal:  Hepatol Commun       Date:  2018-04-16

6.  Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis.

Authors:  Ting Xie; Yizhou Wang; Nan Deng; Guanling Huang; Forough Taghavifar; Yan Geng; Ningshan Liu; Vrishika Kulur; Changfu Yao; Peter Chen; Zhengqiu Liu; Barry Stripp; Jie Tang; Jiurong Liang; Paul W Noble; Dianhua Jiang
Journal:  Cell Rep       Date:  2018-03-27       Impact factor: 9.423

Review 7.  A General Overview on Non-coding RNA-Based Diagnostic and Therapeutic Approaches for Liver Diseases.

Authors:  Sanchari Roy; Christian Trautwein; Tom Luedde; Christoph Roderburg
Journal:  Front Pharmacol       Date:  2018-08-15       Impact factor: 5.810

Review 8.  The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Amanda Hanson; Danielle Wilhelmsen; Johanna K DiStefano
Journal:  Noncoding RNA       Date:  2018-08-21

Review 9.  Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets.

Authors:  B Alipoor; S Nikouei; F Rezaeinejad; S-N Malakooti-Dehkordi; Z Sabati; H Ghasemi
Journal:  J Endocrinol Invest       Date:  2021-04-01       Impact factor: 4.256

Review 10.  Extracellular Vesicles as Carriers of Non-coding RNAs in Liver Diseases.

Authors:  Junfa Yang; Changyao Li; Lei Zhang; Xiao Wang
Journal:  Front Pharmacol       Date:  2018-04-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.